Related Post:

• Clinical Treatment CBP501 Receives FDA Orphan Drug Designation for Mesothelioma

  CBP501, made by CanBas Co., is being tested as a treatment for mesothelioma. With the FDA's recent Orphan Drug Designation, the company can now receive ...

• Photodynamic Therapy For Mesothelioma Patients Should Improve With PHOTOFRIN Approval

  Photodynamic therapy (PDT) for mesothelioma patients got a boost when PHOTOFRIN obtained Orphan Drug Designation. PHOTOFRIN is often prescribed following surgery and chemotherapy for malignant ...

• Mesothelioma Treatment Phase II Clinical Trial Offers Hope

  The biotechnology company MolMed, based in Italy, has announced positive results for their Phase II trial of NGR-hTNF for the treatment of malignant pleural mesothelioma. ...

• Mesothelioma Center Week In Review: A Look To the Future, A Glance At the Past for Mesothelioma

  Asbestos abatement violators go to trial, Orphan Drug Designation comes alive, Steve McQueen and Warren Zevon all take the stage at the Mesothelioma Center this ...

• Mesothelioma Clinical Trial in Italy Tests the Use of NGR-hTNF

  In a recent press release issued by MolMed S.p.A., an Italian biotechnology company, a Phase III clinical trial for malignant pleural mesothelioma patients has begun ...